血管紧张素转换酶抑制剂使用者的高发咳嗽

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL

Bahrain Medical Bulletin Pub Date : 2018-06-01 DOI:10.12816/0047558

J. Nasser, Khadija Al Aradi, K. S. Ebrahim

{"title":"血管紧张素转换酶抑制剂使用者的高发咳嗽","authors":"J. Nasser, Khadija Al Aradi, K. S. Ebrahim","doi":"10.12816/0047558","DOIUrl":null,"url":null,"abstract":"Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.","PeriodicalId":43814,"journal":{"name":"Bahrain Medical Bulletin","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"High Incidence of Cough among Users of Angiotensin-Converting Enzyme Inhibitors\",\"authors\":\"J. Nasser, Khadija Al Aradi, K. S. Ebrahim\",\"doi\":\"10.12816/0047558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.\",\"PeriodicalId\":43814,\"journal\":{\"name\":\"Bahrain Medical Bulletin\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2018-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bahrain Medical Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12816/0047558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bahrain Medical Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12816/0047558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 3

摘要

高血压的药理学治疗包括许多主要类别的药物。血管紧张素转换酶抑制剂（ACEI）就是其中之一。事实上，在最近的许多指南中，ACEI被认为是首选3，4。ACEI除了降压外，还有许多适应症。例如，许多研究发现，对心肌梗死后、心力衰竭和慢性肾脏疾病患者具有一致的有益效果5。这导致了这些制剂的广泛使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

High Incidence of Cough among Users of Angiotensin-Converting Enzyme Inhibitors

Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bahrain Medical Bulletin MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

50.00%

发文量

期刊介绍： The Bahrain Medical Bulletin is published every three months appearing in March, June, September and December. It is indexed in the World Health Organization Index Medicus for Eastern Mediterranean Region (IMEMRI), Extramed of the United Kingdom and International Serial Data System of France. Everything we publish is freely available online throughout the world, for you to read, download, copy, distribute, and use (with attribution) any way you wish. No permission required.